Quantum Biopharma (NASDAQ:QNTM - Get Free Report) was upgraded by stock analysts at Singular Research to a "moderate buy" rating in a research report issued on Wednesday,Zacks.com reports.
Separately, Wall Street Zen upgraded Quantum Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, June 7th.
View Our Latest Stock Analysis on QNTM
Quantum Biopharma Stock Up 16.0%
QNTM opened at $35.00 on Wednesday. The business has a fifty day moving average of $11.65 and a 200 day moving average of $7.58. Quantum Biopharma has a 52-week low of $2.70 and a 52-week high of $38.25. The stock has a market cap of $101.85 million, a P/E ratio of -2.19 and a beta of 0.55.
Quantum Biopharma (NASDAQ:QNTM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($1.04). The company had revenue of $2.09 million during the quarter, compared to the consensus estimate of $2.09 million. Equities analysts anticipate that Quantum Biopharma will post -3.27 EPS for the current fiscal year.
Institutional Investors Weigh In On Quantum Biopharma
An institutional investor recently raised its position in Quantum Biopharma stock. AdvisorShares Investments LLC grew its position in Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) by 163.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 69,078 shares of the company's stock after buying an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned 3.60% of Quantum Biopharma worth $254,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.24% of the company's stock.
Quantum Biopharma Company Profile
(
Get Free Report)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Quantum Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum Biopharma wasn't on the list.
While Quantum Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
